title: Complete resolution of enterocolic fistulas with infliximab.
abstract: Fistulas are a frequent and serious complication of Crohn's disease. Most of the literature has been focused on perianal fistulas, which are by far the most frequent. The effectiveness of treatment with infliximab in fistulizing Crohn's disease was demonstrated in the ACCENT II trial. In that study, however, all patients had external fistulas, and the majority of those were perianal fistulas. The response to fistula treatment in other locations was not evaluated.
authors.affiliation: Inflammatory Bowel Disease Clinic, Department of Gastroenterology and Hepatology, Hospital de Santa Maria, Lisbon, Portugal. joanamnunes@gmail.com
authors.forename: Joana
authors.initials: J
authors.lastname: Nunes
authors.forename: Paula M
authors.initials: PM
authors.lastname: Santos
authors.forename: Lourdes
authors.initials: L
authors.lastname: Tavares
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003108:Colonic Diseases / Q000188:drug therapy* / Q000209:etiology; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab